Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary anti-cancer activity of PUR001, an anti-CD39
monoclonal antibody, in adult patients with advanced solid tumors, as monotherapy. A "3+3"
design will be used to determine MTD and RP2D. .